QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Prothena Stock Price, News & Analysis (NASDAQ:PRTA)

$32.48
-0.02 (-0.06%)
(As of 11/28/2023 ET)
Compare
Today's Range
$31.84
$32.62
50-Day Range
$32.31
$52.50
52-Week Range
$28.51
$79.65
Volume
395,316 shs
Average Volume
507,182 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$91.00

Prothena MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
180.2% Upside
$91.00 Price Target
Short Interest
Bearish
11.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Prothena in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.76) to ($4.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

470th out of 949 stocks

Pharmaceutical Preparations Industry

216th out of 435 stocks


PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

PRTA Dec 2023 105.000 call
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Cantor Fitzgerald Keeps Their Buy Rating on Prothena (PRTA)
Piper Sandler Keeps Their Buy Rating on Prothena (PRTA)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Earnings Preview For Prothena Corp
5 Biotech Stocks Set to Outpace Q3 Earnings Estimates
Prothena Corp. exploring a potential sale - Bloomberg
Prothena shares buoyed by sale rumors
Piper Sandler Remains a Buy on Prothena (PRTA)
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
127
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$91.00
High Stock Price Target
$129.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+180.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-116,950,000.00
Pretax Margin
-61.37%

Debt

Sales & Book Value

Annual Sales
$53.90 million
Book Value
$12.86 per share

Miscellaneous

Free Float
38,531,000
Market Cap
$1.74 billion
Optionable
Optionable
Beta
0.45
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

7 Wall Street analysts have issued 1-year price objectives for Prothena's stock. Their PRTA share price targets range from $72.00 to $129.00. On average, they anticipate the company's share price to reach $91.00 in the next year. This suggests a possible upside of 180.2% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2023?

Prothena's stock was trading at $60.25 at the beginning of 2023. Since then, PRTA stock has decreased by 46.1% and is now trading at $32.48.
View the best growth stocks for 2023 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.64. The biotechnology company earned $84.87 million during the quarter, compared to analysts' expectations of $51.85 million. Prothena had a negative trailing twelve-month return on equity of 12.06% and a negative net margin of 51.92%.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.96%), Rock Springs Capital Management LP (1.14%), Bank of New York Mellon Corp (0.93%), Northern Trust Corp (0.76%), JPMorgan Chase & Co. (0.75%) and Avidity Partners Management LP (0.71%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -